In this blog, we provide a rapid overview of the sources and wider uses of medicines data to strengthen health systems in LMIC settings, with a focus on Ghana. We argue that having credible and comprehensive data on medicines use leads to better decision making and better medicines policy. These are necessary—although not sufficient—pre-conditions to improve health outcomes in a financially sustainable way.
CGD Policy Blogs
In this blog, we explore three key actions linked to strategic purchasing that India’s AB-PMJAY scheme can apply by leveraging its influence as a major purchaser of services and goods in the country. These same actions are readily generalizable and can replicated by other jurisdictions to save money, improve health and accelerate a country’s journey towards UHC.
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
The UK example has some key lessons for all countries (including the UK itself) who are considering how to improve their current response, and how to “build back better” and prepare for future pandemics.